Ankylosing Spondylitis Market Report 2025

The ankylosing spondylitis market size has grown strongly in recent years. It will grow from $5.9 billion in 2024 to $6.36 billion in 2025 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to hla-b27 discovery, biologic treatments development, pain management approaches, patient advocacy and awareness, NSAIDS and disease modifying drugs.

The ankylosing spondylitis market size is expected to see strong growth in the next few years. It will grow to $8.71 billion in 2029 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to personalized medicine approach, novel biologics development, early intervention and screening, lifestyle and diet management, telemedicine and remote monitoring. Major trends in the forecast period include biosimilar availability, targeted pain therapies, patient-reported outcomes (pros) emphasis, community support programs, regenerative medicine exploration.

The growing geriatric population is expected to drive the expansion of the ankylosing spondylitis market in the coming years. The geriatric population refers to the increasing proportion of elderly individuals resulting from changes in a population's age structure. This demographic shift has led to a rise in the number and proportion of people over the age of 60. Treatment and medication for ankylosing spondylitis play a crucial role in improving mobility and managing pain in elderly individuals affected by this condition. For example, in January 2023, the United Nations Department of Economic and Social Affairs (UN DESA), a US-based division of the UN Secretariat, reported that the global population of individuals aged 65 and older is projected to more than double, rising from 761 million in 2021 to 1.6 billion by 2050. As a result, the growing geriatric population is fueling the growth of the ankylosing spondylitis market.

The rising prevalence of autoimmune diseases is set to further boost the ankylosing spondylitis market. Autoimmune diseases encompass a wide range of disorders caused by abnormal immune responses, where the immune system mistakenly attacks and damages healthy cells, tissues, and organs. In the case of ankylosing spondylitis, the immune system incorrectly targets the body's own tissues, leading to inflammation and damage, particularly affecting the spine and pelvis. Genetic predisposition and environmental factors are key contributors to the development of this autoimmune condition. For instance, in September 2023, the IBD Clinical and Research Centre, a Canada-based organization focused on improving the lives of patients with Crohn's disease and ulcerative colitis, published the Impact of IBD Report 2023. The report revealed that with a prevalence rate of 825 per 100,000, over 320,000 Canadians had inflammatory bowel disease (IBD) in 2023, and this prevalence is expected to rise by 2.44% annually, with 1.1% of the population (470,000 Canadians) projected to be living with IBD by 2035. Consequently, the rising incidence of autoimmune diseases will drive the future growth of the ankylosing spondylitis market.

Advancements in therapeutic options are a notable trend gaining traction in the ankylosing spondylitis market. Companies in the ankylosing spondylitis space are continuously innovating new therapeutic solutions to maintain their market presence. For instance, in April 2022, AbbVie Inc., a US-based biopharmaceutical company, announced the U.S. Food and Drug Administration's (FDA) approval of RINVOQ for treating adults with active ankylosing spondylitis (AS). This new oral treatment is intended for patients who have not responded to TNF blockers, providing significant improvements in symptoms such as back pain and physical function. Its rapid efficacy and positive safety profile from clinical trials make it a valuable addition to managing this chronic inflammatory condition, thereby expanding therapeutic options for patients.

Leading companies in ankylosing spondylitis are focusing on developing innovative drugs, such as those based on enzymatic and cellular assays, to treat moderately to severely active rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, Crohn’s disease, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Drugs developed using enzymatic and cellular assays are created and validated by testing their effects on specific enzymes or cell systems, allowing for more targeted and precise treatments. For example, in April 2022, AbbVie Inc. secured FDA approval for RINVOQ as a treatment for ankylosing spondylitis (AS). RINVOQ, a selective JAK inhibitor being investigated across multiple immune-mediated inflammatory conditions, demonstrates heightened inhibitory potency for JAK-1 over JAK-2, JAK-3, and TYK-2, based on enzymatic and cellular assay data.

In July 2023, Superior Biologics, Inc., a US-based specialty pharmacy and home infusion therapy service provider, and Coherus BioSciences, Inc. announced a national distribution agreement. This collaboration aims to distribute YUSIMRY, a biosimilar to Humira, across the US, offering patients an affordable and high-quality treatment for autoimmune conditions like ankylosing spondylitis, rheumatoid arthritis, and Crohn's disease. The partnership also helps employers reduce specialty drug costs by over 85%. Coherus BioSciences Inc. is a US-based biopharmaceutical company that provides YUSIMRY (adalimumab-aqvh), a biosimilar product for treating ankylosing spondylitis (AS).

Major companies operating in the ankylosing spondylitis market include Pfizer Inc., Johnson & Johnson Pvt. Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Bristol-Myers Squibb, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Amgen Inc., Cedars-Sinai, Viatris Inc., Astellas Pharma Inc., AstraZeneca plc, UCB Inc., Cipla Inc., Zydus Lifesciences Limited, Celltrion Inc., Hetero Labs Ltd., UCSF Health, Janssen Biotech Inc., Reliance Life Sciences Pvt. Ltd.

North America was the largest region in the ankylosing spondylitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ankylosing spondylitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the ankylosing spondylitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Ankylosing spondylitis (AS) is a chronic inflammatory condition primarily affecting the spine and sacroiliac joints, causing inflammation in the joints and entheses, leading to pain, stiffness, and progressive loss of spinal mobility.

The main treatment modalities for ankylosing spondylitis include painkillers and non-steroidal anti-inflammatory drugs (NSAIDs), disease-modifying anti-rheumatic drugs (DMARDs), biological therapies, steroids, physical therapies, and surgery. Painkillers and NSAIDs are medications that inhibit the production of specific chemicals causing pain and swelling, aiming to relieve pain and reduce inflammation in AS treatment. Biologics, biosimilars, and small molecules are administered through various routes, including parenteral and oral, catering to both juvenile and adult populations. These treatments are employed by hospitals, clinics, research laboratories, and other end-users.

The ankylosing spondylitis market research report is one of a series of new reports that provides ankylosing spondylitis market statistics, including ankylosing spondylitis industry global market size, regional shares, competitors with an ankylosing spondylitis market share, detailed ankylosing spondylitis market segments, market trends and opportunities, and any further data you may need to thrive in the ankylosing spondylitis industry. This ankylosing spondylitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The ankylosing spondylitis market consists of sales of nonsteroidal anti-inflammatory drugs, disease-modifying antirheumatic drugs (DMARDs), tumor necrosis factor (TNF) inhibitors, interleukin inhibitors, and corticosteroids. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.